- Home
- EPRX vs STHO Comparison
EPRX vs STHO Comparison
Compare EPRX & STHO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPRX
- STHO
- Stock Information
- Founded
- EPRX 2011
- STHO N/A
- Country
- EPRX Canada
- STHO United States
- Employees
- EPRX N/A
- STHO N/A
- Industry
- EPRX
- STHO Real Estate
- Sector
- EPRX
- STHO Real Estate
- Exchange
- EPRX NYSE
- STHO Nasdaq
- Market Cap
- EPRX 130.0M
- STHO 117.1M
- IPO Year
- EPRX N/A
- STHO N/A
- Fundamental
- Price
- EPRX $3.28
- STHO $7.98
- Analyst Decision
- EPRX Strong Buy
- STHO
- Analyst Count
- EPRX 1
- STHO 0
- Target Price
- EPRX $9.00
- STHO N/A
- AVG Volume (30 Days)
- EPRX 11.9K
- STHO 115.2K
- Earning Date
- EPRX 05-07-2025
- STHO 05-09-2025
- Dividend Yield
- EPRX N/A
- STHO N/A
- EPS Growth
- EPRX N/A
- STHO N/A
- EPS
- EPRX N/A
- STHO N/A
- Revenue
- EPRX N/A
- STHO $113,297,000.00
- Revenue This Year
- EPRX N/A
- STHO N/A
- Revenue Next Year
- EPRX N/A
- STHO N/A
- P/E Ratio
- EPRX N/A
- STHO N/A
- Revenue Growth
- EPRX N/A
- STHO N/A
- 52 Week Low
- EPRX $2.20
- STHO $7.96
- 52 Week High
- EPRX $4.48
- STHO $14.50
- Technical
- Relative Strength Index (RSI)
- EPRX N/A
- STHO 41.71
- Support Level
- EPRX N/A
- STHO $7.97
- Resistance Level
- EPRX N/A
- STHO $8.91
- Average True Range (ATR)
- EPRX 0.00
- STHO 0.35
- MACD
- EPRX 0.00
- STHO -0.00
- Stochastic Oscillator
- EPRX 0.00
- STHO 1.07
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.
About STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. It focuses on realizing value for shareholders from the legacy portfolio by maximizing cash flows through active asset management and asset sales.